Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision mak...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1152467/full |
| _version_ | 1827990892772851712 |
|---|---|
| author | Giovanni Manfredi Assanto Ilaria Del Giudice Irene Della Starza Irene Della Starza Roberta Soscia Marzia Cavalli Mattia Cola Vittorio Bellomarino Mariangela Di Trani Anna Guarini Robin Foà |
| author_facet | Giovanni Manfredi Assanto Ilaria Del Giudice Irene Della Starza Irene Della Starza Roberta Soscia Marzia Cavalli Mattia Cola Vittorio Bellomarino Mariangela Di Trani Anna Guarini Robin Foà |
| author_sort | Giovanni Manfredi Assanto |
| collection | DOAJ |
| description | Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice. |
| first_indexed | 2024-04-10T00:42:30Z |
| format | Article |
| id | doaj.art-154cdd8a16554ff688943c29eaa258df |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T00:42:30Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-154cdd8a16554ff688943c29eaa258df2023-03-14T04:55:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11524671152467Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?Giovanni Manfredi Assanto0Ilaria Del Giudice1Irene Della Starza2Irene Della Starza3Roberta Soscia4Marzia Cavalli5Mattia Cola6Vittorio Bellomarino7Mariangela Di Trani8Anna Guarini9Robin Foà10Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyGruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Fondazione GIMEMA Franco Mandelli Onlus, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyDepartment of Molecular Medicine, Sapienza University, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyMinimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice.https://www.frontiersin.org/articles/10.3389/fonc.2023.1152467/fulldigital droplet PCRmeasurable residual disease (MRD)non-Hodgkin lymphomachronic lymphocytic leukemiahairy cell leukaemia (HCL) |
| spellingShingle | Giovanni Manfredi Assanto Ilaria Del Giudice Irene Della Starza Irene Della Starza Roberta Soscia Marzia Cavalli Mattia Cola Vittorio Bellomarino Mariangela Di Trani Anna Guarini Robin Foà Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? Frontiers in Oncology digital droplet PCR measurable residual disease (MRD) non-Hodgkin lymphoma chronic lymphocytic leukemia hairy cell leukaemia (HCL) |
| title | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
| title_full | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
| title_fullStr | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
| title_full_unstemmed | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
| title_short | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
| title_sort | research topic measurable residual disease in hematologic malignancies can digital droplet pcr improve measurable residual disease monitoring in chronic lymphoid malignancies |
| topic | digital droplet PCR measurable residual disease (MRD) non-Hodgkin lymphoma chronic lymphocytic leukemia hairy cell leukaemia (HCL) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1152467/full |
| work_keys_str_mv | AT giovannimanfrediassanto researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT ilariadelgiudice researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT irenedellastarza researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT irenedellastarza researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT robertasoscia researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT marziacavalli researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT mattiacola researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT vittoriobellomarino researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT mariangeladitrani researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT annaguarini researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT robinfoa researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies |